On June 27, a new weight loss drug was approved by the FDA. With the growing problem of obesity in the US, the drug represents a new tool in the treatment of obesity. Called Lorcaserin or Belviq, the drug shows an average weight loss of 5 percent compared to a placebo and is expected to be available before the end of summer, though the FDA does require ongoing study of the medication.
As with any weight loss drug, Lorcaserin works best in combination with a comprehensive weight loss program. Programs that focus on lifestyle change or behavior modification, nutrition education, and exercise are vital to the success of any weight loss patient. Other medications like Xenical and Alli are currently available for obesity treatment, while phentermine may be prescribed for short-term use.
In July, the FDA will vote on the approval of another weight loss drug, QNEXA. QNEXA is a combination of lower doses of phentermine and topiramate and has so far shown an average weight loss of 10 percent.
Talk to your CONCI physician to see if these drugs may be part of your treatment plan. We will keep you posted as new information is available.